These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 8061896)

  • 1. Adoptive immunotherapy of murine intracerebral tumors with anti-CD3/interleukin-2-activated tumor-draining lymph node cells.
    Wahl WL; Sussman JJ; Shu S; Chang AE
    J Immunother Emphasis Tumor Immunol; 1994 May; 15(4):242-50. PubMed ID: 8061896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of interleukin-1 alpha on the in vitro activation of tumor-draining lymph node cells for adoptive immunotherapy.
    Hammel JM; Tuck MK; Hain JM; Chang AE; Sondak VK
    J Immunother Emphasis Tumor Immunol; 1994 Jul; 16(1):1-12. PubMed ID: 8081555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic effects of tumor reactive CD4+ cells generated from tumor-primed lymph nodes using anti-CD3/anti-CD28 monoclonal antibodies.
    Li Q; Yu B; Grover AC; Zeng X; Chang AE
    J Immunother; 2002; 25(4):304-13. PubMed ID: 12142553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-induced suppression of antitumor reactivity and depression of TCRzeta expression in tumor-draining lymph node lymphocytes: possible relationship to the Th2 pathway.
    Fu EJ; Arca MJ; Hain JM; Krinock R; Rado J; Cameron MJ; Chang AE; Sondak VK
    J Immunother; 1997 Mar; 20(2):111-22. PubMed ID: 9087383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.
    Yoshizawa H; Chang AE; Shu S
    J Immunol; 1991 Jul; 147(2):729-37. PubMed ID: 1830072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor reactivity of anti-CD3/anti-CD28 bead-activated lymphoid cells: implications for cell therapy in a murine model.
    Ito F; Carr A; Svensson H; Yu J; Chang AE; Li Q
    J Immunother; 2003; 26(3):222-33. PubMed ID: 12806276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of T-cells reactive to the poorly immunogenic B16-BL6 melanoma with efficacy in the treatment of spontaneous metastases.
    Geiger JD; Wagner PD; Cameron MJ; Shu S; Chang AE
    J Immunother Emphasis Tumor Immunol; 1993 Apr; 13(3):153-65. PubMed ID: 8471590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells.
    Li Q; Grover AC; Donald EJ; Carr A; Yu J; Whitfield J; Nelson M; Takeshita N; Chang AE
    J Immunol; 2005 Aug; 175(3):1424-32. PubMed ID: 16034078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
    Inoue M; Plautz GE; Shu S
    Cancer Res; 1996 Oct; 56(20):4702-8. PubMed ID: 8840987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-reactivity of anti-CD3/IL-2 activated effector cells derived from lymph nodes draining heterologous clones of a murine tumor.
    Matsumura T; Krinock RA; Chang AE; Shu S
    Cancer Res; 1993 Sep; 53(18):4315-21. PubMed ID: 8364926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of T cells generated from lymph nodes draining the SEA-expressing murine B16 melanoma and secondarily activated with dendritic cells.
    Yu J; Tian R; Xiu B; Yan J; Jia R; Zhang L; Chang AE; Song H; Li Q
    Int J Biol Sci; 2009; 5(2):135-46. PubMed ID: 19173035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoptive immunotherapy mediated by anti-TCR/IL-2-activated tumour-draining lymph node cells.
    Mitsuma S; Yoshizawa H; Ito K; Moriyama H; Wakabayashi M; Chou T; Arakawa M; Shu S
    Immunology; 1994 Sep; 83(1):45-51. PubMed ID: 7821965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different cytokine profiles released by CD4+ and CD8+ tumor-draining lymph node cells involved in mediating tumor regression.
    Aruga A; Aruga E; Cameron MJ; Chang AE
    J Leukoc Biol; 1997 Apr; 61(4):507-16. PubMed ID: 9103238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive immunotherapy of advanced tumors with CD62 L-selectin(low) tumor-sensitized T lymphocytes following ex vivo hyperexpansion.
    Wang LX; Chen BG; Plautz GE
    J Immunol; 2002 Sep; 169(6):3314-20. PubMed ID: 12218152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo antitumor efficacy of tumor-draining lymph node cells activated with nonspecific T-cell reagents.
    Shu S; Sussman JJ; Chang AE
    J Immunother Emphasis Tumor Immunol; 1993 Nov; 14(4):279-85. PubMed ID: 8280709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy.
    Li Q; Carr A; Ito F; Teitz-Tennenbaum S; Chang AE
    Cancer Res; 2003 May; 63(10):2546-52. PubMed ID: 12750278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent effector function of tumor-sensitized L-selectin(low) T cells against subcutaneous tumors requires LFA-1 co-stimulation.
    Seeley BM; Barthel SW; To WC; Kjaergaard J; Shu S; Plautz GE
    Otolaryngol Head Neck Surg; 2001 Apr; 124(4):436-41. PubMed ID: 11283503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells.
    Yoshizawa H; Chang AE; Shu SY
    Cancer Res; 1992 Mar; 52(5):1129-36. PubMed ID: 1531321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic effects of IL-12 and IL-18 in skewing tumor-reactive T-cell responses towards a type 1 pattern.
    Li Q; Carr AL; Donald EJ; Skitzki JJ; Okuyama R; Stoolman LM; Chang AE
    Cancer Res; 2005 Feb; 65(3):1063-70. PubMed ID: 15705908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific immunotherapy with tumour-draining lymph node cells cultured with both anti-CD3 and anti-CD28 monoclonal antibodies.
    Harada M; Okamoto T; Omoto K; Tamada K; Takenoyama M; Hirashima C; Ito O; Kimura G; Nomoto K
    Immunology; 1996 Mar; 87(3):447-53. PubMed ID: 8778032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.